Highlight
This large within-individual observational study conducted in Sweden finds that treatment with glucagon-like peptide-1 (GLP-1) receptor agonists is significantly associated with a lower risk of hospital admissions related to alcohol use disorder (AUD) and other substance use disorders (SUDs) during active treatment periods. The protective association persists up to six months after stopping GLP-1 therapy for alcohol-related hospitalisations but not for other substance use disorder events. In contrast, dipeptidyl peptidase-4 (DPP-4) inhibitors, another class of diabetes medications, show no consistent effect on such hospitalisations.
